Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. An Investigation Of Plasma Cell-free Rna For The Detection Of Colorectal Cancer: From Transcriptome Marker Selection To Targeted Validation.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. An Investigation Of Plasma Cell-free Rna For The Detection Of Colorectal Cancer: From Transcriptome Marker Selection To Targeted Validation.

Related Experiment Video

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K

An investigation of plasma cell-free RNA for the detection of colorectal cancer: From transcriptome marker selection to targeted validation.

Emmalee J Northrop-Albrecht1, Chung Wah Wu1, Calise K Berger1

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States of America.

Plos One
|August 15, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Researchers explored plasma cell-free RNA (cfRNA) for early colorectal cancer (CRC) detection. While optimizing methods, few cfRNA candidates showed clinical utility, highlighting the need for further research in liquid biopsy development.

More Related Videos

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
15:17

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

13.9K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.3K

Related Experiment Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
15:17

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing

Published on: September 25, 2011

13.9K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomarker Discovery

Background:

  • Colorectal cancer (CRC) remains a significant cause of cancer-related deaths, necessitating improved early detection methods.
  • Non-invasive biomarkers, such as plasma cell-free RNA (cfRNA), are of great interest for diagnostic applications.
  • Current CRC screening methods have limitations, driving the search for more effective alternatives.

Purpose of the Study:

  • To identify and validate potential cfRNA candidates for early colorectal cancer diagnosis.
  • To establish a methodological framework for future plasma RNA studies.
  • To assess the clinical utility of identified cfRNA candidates for early CRC detection.

Main Methods:

  • Phase 1: Discovery RNA sequencing in plasma from CRC patients and controls (n=49).
  • Phase 2: Targeted capture sequencing for validation of selected exons (n=73).
  • Phase 3: Reverse transcription quantitative PCR (RT-qPCR) for candidate validation (n=57).

    • Main Results:

    • 895 differentially expressed exons were identified between CRC and control groups.
    • Limited validation of candidate cfRNA markers in independent patient sets was observed.
    • Optimized laboratory processes and data analysis strategies were developed.

    Conclusions:

    • The study optimized processes for plasma cfRNA analysis, providing a framework for future liquid biopsy research.
    • Further investigation is required to determine the clinical utility of the identified cfRNA candidates for early CRC detection.
    • Advancements in technology and methodology are crucial for improving the reproducibility and feasibility of RNA-based liquid biopsies.